Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gatifloxacin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Besifloxacin | EXPERIMENTAL | Besifloxacin one drop instilled into study eye. |
| Gatifloxacin | ACTIVE_COMPARATOR | Gatifloxacin one drop instilled into study eye. |
| Moxifloxacin | ACTIVE_COMPARATOR | Moxifloxacin one drop instilled into study eye. |
| Name | Type | Description |
|---|---|---|
| Gatifloxacin | DRUG | Gatifloxacin 0.3% one drop instilled into study eye at visit 2. |
| Moxifloxacin | DRUG | Moxifloxacin 0.5% one drop instilled into study eye at visit 2. |
| Besifloxacin | DRUG | Besifloxacin 0.6% one drop instilled into study eye at visit 2. |
Inclusion Criteria: * Willing to avoid all disallowed medications for the appropriate washout periods. * Have a best corrected visual acuity of 0.60 logMAR or better in each eye as measured using an ETDRS chart. Exclusion Criteria: * Have a known allergy and/or sensitivity to the test articles or...
Gatifloxacin is a small molecule drug being developed by Bausch + Lomb Corporation (BLCO). It is currently in Phase 1 clinical development. Gatifloxacin is an antibiotic that has been studied for its concentration in human conjunctiva after topical instillation.
Gatifloxacin is being studied for use in healthy volunteers to measure its concentration in the human conjunctiva after topical instillation. The drug is in Phase 1 clinical development for this purpose. It is not yet approved for any indication.
Gatifloxacin is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is conducting clinical research on this small molecule drug, which is currently in Phase 1 development.
Gatifloxacin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a clinical trial to evaluate its concentration in human conjunctiva after topical instillation.
Gatifloxacin is associated with one completed Phase 1 clinical trial, NCT00905762, titled "Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation." The trial enrolled 119 healthy participants in the United States and was double-blind with an active control.
Gatifloxacin is a distinct drug from Besifloxacin and Moxifloxacin, though they were studied together in a clinical trial. The trial NCT00905762 compared the concentration of these three antibiotics in human conjunctiva after topical instillation. Each is a separate fluoroquinolone antibiotic.